Literature DB >> 12899717

Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes.

Shin-ichiro Fujii1, Kanako Shimizu, Virginia Klimek, Matthew D Geller, Stephen D Nimer, Madhav V Dhodapkar.   

Abstract

Here we show that patients with myelodysplastic syndromes (MDS) have a severe deficiency of glycolipid reactive Valpha24+/Vbeta11+ natural killer T (NKT) cells, but not NK cells or CD4+ or CD8+ T cells. Neither the blood nor marrow of MDS patients had detectable interferon-gamma-producing NKT cells in response to the NKT ligand, alpha-galactosyl ceramide, although influenza-virus-specific effector T-cell function was preserved. This severe and selective deficiency of an important immune regulatory cell may contribute to the pathogenesis of MDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12899717     DOI: 10.1046/j.1365-2141.2003.04465.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  47 in total

1.  Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia.

Authors:  Farhad Jadidi-Niaragh; Mahmood Jeddi-Tehrani; Bita Ansaripour; Seyed Mohsen Razavi; Ramazan Ali Sharifian; Fazel Shokri
Journal:  Med Oncol       Date:  2012-06-06       Impact factor: 3.064

Review 2.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

Review 3.  Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.

Authors:  Leonid S Metelitsa
Journal:  Clin Immunol       Date:  2010-11-20       Impact factor: 3.969

4.  Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient.

Authors:  Caterina Stefanizzi; Massimo Breccia; Michelina Santopietro; Serelina Coluzzi; Laura Cannella; Gabriella Girelli; Giuliana Alimena
Journal:  Int J Hematol       Date:  2009-05-26       Impact factor: 2.490

Review 5.  Application of natural killer T-cells to posttransplantation immunotherapy.

Authors:  Shin-ichiro Fujii
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

6.  Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Authors:  Mark A Exley; Phillip Friedlander; Nadia Alatrakchi; Lianne Vriend; Simon Yue; Tetsuro Sasada; Wanyong Zeng; Yo Mizukami; Justice Clark; David Nemer; Kenneth LeClair; Christine Canning; Heather Daley; Glenn Dranoff; Anita Giobbie-Hurder; F Stephen Hodi; Jerome Ritz; Steven P Balk
Journal:  Clin Cancer Res       Date:  2017-02-13       Impact factor: 12.531

Review 7.  Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.

Authors:  Mathias Oelke; Jonathan P Schneck
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

8.  Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.

Authors:  Tonya J Webb; Joan G Bieler; Jonathan P Schneck; Mathias Oelke
Journal:  J Immunol Methods       Date:  2009-05-14       Impact factor: 2.303

9.  Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.

Authors:  Weihua Song; Hans J J van der Vliet; Yu-Tzu Tai; Rao Prabhala; Ruojie Wang; Klaus Podar; Laurence Catley; Masood A Shammas; Kenneth C Anderson; Steven P Balk; Mark A Exley; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 10.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.